Galectin-3 in Liver Fibrosis
Galectin-3 in Liver Fibrosis
批准号:
9062424
负责人:
Xiaosong Joy Jiang
金额:
$13.14万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-03-01 至 2017-09-30
关键词:
AddressAntigen PresentationAntigen-Presenting CellsApoptoticBindingBiological Response ModifiersCD4 Positive T LymphocytesCellsCirrhosisCitrusCoculture TechniquesCollagenCollagen Type IDataDevelopmentEventExtracellular MatrixFamilyFibrosisFutureGalactosidesGalectin 2Galectin 3HepaticHepatic FibrogenesisHepatic Stellate CellHepatocyteImmuneImmune responseInflammatoryIntegrinsLeadLectinLifeLigationLiver FibrosisLymphocyte SubsetMediatingMediator of activation proteinModalityModelingMusPectinsPeritoneal MacrophagesPhagocytosisPlayProcessProcollagenReactionRegulationRoleSignal PathwayTestingTransforming Growth FactorsUp-Regulationbile ductcytokinefibrogenesisimmunoregulationin vivoinhibitor/antagonistinjuredmembernovel therapeutic interventionnovel therapeuticspreventresponsestellate cell
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hepatic stellate cells (HSC) play a crucial role during liver fibrogenesis. Phagocytosis of apoptotic bodies from hepatocytes induces HSC activation with upregulation of procollagen alpha 1(I) and TGF-ß expression. In addition, recent data indicate that HSC behave as antigen presenting cells (APC). However, their role in the regulation of hepatic immune responses during fibrogenesis is not well understood. Galectin-3 (Gal3), a member of 2-galactoside-binding lectin family is known to regulate cell phagocytosis and also is an important immune regulator. According to our preliminary data Gal3 is an important mediator of liver fibrosis as Gal3 deficient HSC displayed decreased phagocytic activity and diminished profibrogenic activity and Gal3-/- mice developed decreased fibrosis. Therefore, our hypothesis is that Gal3 plays a role in liver fibrosis by regulating HSC phagocytosis and antigen presentation, and the subsequent immune responses. To test this hypothesis, our specific aims are 1) to study the mechanisms by which Gal3 regulates phagocytosis, 2) the role of Gal3 in the regulation of immune responses during liver fibrosis, and 3) the in vivo effects of Gal3 on profibrogenesis and immunoregulation will be studied. In addition, we will use the Gal3 inhibitor modified citrus pectin (MCP) in the in vivo fibrosis model to assess its antifibrogenic activity. These studies may lead to the development of new therapeutic modalities aimed at reversing or preventing liver fibrosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fumarates for Alcoholic Liver Disease
-
批准号:10700042
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2022
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Fumarates for Alcoholic Liver Disease
-
批准号:10452220
-
项目类别:
-
资助金额:$19.09万
-
财政年份:2022
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Galectin-3 in Primary biliary Cirrhosis
-
批准号:8954302
-
项目类别:
-
资助金额:$7.82万
-
财政年份:2015
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Galectin-3 in Primary biliary Cirrhosis
-
批准号:9070672
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2015
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Galectin-3 in Liver Fibrosis
-
批准号:8804260
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2012
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Galectin-3 in Liver Fibrosis
-
批准号:8240889
-
项目类别:
-
资助金额:$9.72万
-
财政年份:2012
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Galectin-3 in Liver Fibrosis
-
批准号:8623129
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2012
-
负责人:Xiaosong Joy Jiang
-
依托单位:
Galectin-3 in Liver Fibrosis
-
批准号:8435400
-
项目类别:
-
资助金额:$9.72万
-
财政年份:2012
-
负责人:Xiaosong Joy Jiang
-
依托单位:
海外基金